Last update:

Immunology news

Oncology & Cancer

Antibody therapy eradicates traces of multiple myeloma in preliminary trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester ...

Oncology & Cancer

Targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single ...

Oncology & Cancer

Antibody halts triple-negative breast cancer in preclinical models

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with ...

Immunology

T cells found in tonsils differ in key ways from those in blood

T cells, also known as lymphocytes, are a type of white blood cell that play an important role in the body's immune response. Historically, blood samples have been used to monitor how T cells respond to a virus, vaccine or ...

Medical research

Why stress can make your hair fall out: A two-part reaction

It's well known that stress can trigger hair loss. A new paper explores how this happens and how our response to stress can have long-term consequences for our scalps, research that may eventually yield insights into autoimmune ...

Immunology

FDA approves updated label for Unloxcyt

The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates ...

Oncology & Cancer

FDA approves Padcev for muscle-invasive bladder cancer

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, as a perioperative neoadjuvant treatment and postcystectomy adjuvant treatment for ...